Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04699604 · ClinicalTrials.gov registry record · Phase 3
A Histamine Pharmacodynamic Biomarker to Guide Treatment in Pediatric Asthma (HAS3)
A Phase 3 study of Allergic Asthma, sponsored by Bridgette Jones.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 300
- Enrollment target
- 1
- Study location
NCT04699604 is a Phase 3 study of Allergic Asthma that is actively recruiting participants, run by Bridgette Jones. The registered enrollment target is 300 participants, above the 131-participant average among 4 other Allergic Asthma trials with a reported enrollment target (129% higher). The trial reports 1 study location across 1 state.
The verdict
NCT04699604, a Phase 3 study of Allergic Asthma, is actively recruiting participants, sponsored by Bridgette Jones.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 300 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a randomized, double-blind, placebo-controlled, crossover study comparing asthma control post treatment in African American/Black and Caucasian/White children in both hyper and hypo responsive HILD (Histamine Lontophoresis with Laser Doppler monitoring) phenotypes with uncontrolled persistent allergic asthma using Levocetirizine (LTZ) vs placebo.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Levocetirizine Dihydrochloride
Study Locations (1)
Missouri
- Children's Mercy Hospital - Kansas City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2021-04-28 |
| Est. Completion | 2026-05-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04699604
The ClinicalTrials.gov registry entry for NCT04699604 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 300 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 131-participant average among 4 other Allergic Asthma trials with a reported enrollment target (129% higher). The listed sponsor is Bridgette Jones, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Allergic Asthma appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT04699604 reports 1 study location spanning 1 distinct geographic area - top geographies include Missouri.
Frequently Asked Questions
What is clinical trial NCT04699604 about?
NCT04699604 is a clinical study titled "A Histamine Pharmacodynamic Biomarker to Guide Treatment in Pediatric Asthma (HAS3)". This is a randomized, double-blind, placebo-controlled, crossover study comparing asthma control post treatment in African American/Black and Caucasian/White children in both hyper and hypo responsive HILD (Histamine Lontophoresis with Laser Doppler monitoring) phenotypes with uncontrolled persisten...
What is the current status of trial NCT04699604?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 300 participants. The study started on 2021-04-28. Estimated completion is 2026-05-01.
What conditions does trial NCT04699604 study?
This clinical trial studies the following conditions: Allergic Asthma.
What interventions are being tested in trial NCT04699604?
The interventions under investigation include: Placebo (DRUG), Levocetirizine Dihydrochloride (DRUG).
Who is sponsoring clinical trial NCT04699604?
This trial is sponsored by Bridgette Jones, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04699604 being conducted?
This trial has 1 study location across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Allergic Asthma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Pharmacosurveillance Data Repository of Patients With and Without History of Anaphylactic Reactions Subsequent to Xolair Dosing
COMPLETED
-
A Study Evaluating the Persistency of Response With or Without Xolair (Omalizumab) After Long-term Therapy
COMPLETED · Phase 4
-
Characterization of the Role of Histamine in Children With Asthma
COMPLETED · Phase 2
-
Effect of Gamma Tocopherol Enriched Supplementation on Response to Inhaled O3 Exposure
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.